Semaglutide Cost in 2026: Ozempic, Wegovy, Insurance

How Much Does Semaglutide Cost? The 2026 Numbers at a Glance

Semaglutide is sold under three brand names by Novo Nordisk, and each has its own price band. The table below is the short answer most people want before reading further. All figures are current as of early 2026 and shift more often than you'd expect, so check the manufacturer site before you fill a prescription.

Ozempic (semaglutide for type 2 diabetes)

Ozempic carries a list price of roughly $900–$1,000 for a 28-day supply, regardless of which strength your prescriber writes (0.25 mg, 0.5 mg, 1.0 mg, or 2.0 mg). Because Ozempic is approved for type 2 diabetes, a long-established indication, it is covered by more commercial plans than its sister drug Wegovy. The Ozempic Savings Card can bring commercially insured patients down to $25/month. Novo Nordisk publishes current terms on the savings page, and the annual benefit cap is not stated publicly in stable form, so check the site before you assume coverage extends to a full year.

Wegovy (semaglutide for weight management)

Wegovy lists higher at $1,350–$1,865 per 28-day supply. The wider band reflects pharmacy markups and dose-pack differences. Wegovy is approved for chronic weight management, an indication that fewer plans cover, which is why its real-world out-of-pocket numbers are far more variable than Ozempic's. The MyWegovy savings card brings commercially insured patients to the same $25/month floor as Ozempic; for cash-pay patients, the NovoCare direct pharmacy is the cheaper route. See the section below.

Rybelsus (oral semaglutide)

Rybelsus was the daily oral form of semaglutide for type 2 diabetes (3 mg, 7 mg, 14 mg); as of 2026 these strengths were reformulated and renamed as the Ozempic pill (1.5/4/9 mg). It is priced differently from the injectables and pharmacy-to-pharmacy variation is wide, so for current retail estimates a GoodRx lookup at your local pharmacy is the most accurate path. Note that the higher-dose oral form approved for weight loss in 2025 is branded as a Wegovy pill, not Rybelsus, so do not assume the pill is automatically cheaper than the pen.

Three price tiers patients actually encounter: list price without insurance, savings-card copay, and NovoCare self-pay.

Insurance Coverage for Semaglutide: What Actually Gets Covered

Insurance is where semaglutide cost gets unpredictable, and the biggest variable is what indication your prescriber writes. Type 2 diabetes is broadly accepted; obesity is not.

Commercial insurance: Ozempic vs Wegovy

Ozempic, prescribed for type 2 diabetes, is covered by most commercial formularies, usually on a higher tier and almost always with prior authorization. Wegovy is the harder one. Some ACA marketplace plans cover it as part of obesity-treatment benefits; many employer plans explicitly carve out anti-obesity medications, which means even a fully employed patient with strong insurance can end up paying close to list price. In published surveys of patients who discontinue GLP-1 therapy, roughly half cite cost or insurance access as a primary reason. That benchmark is a fair gauge of how often the coverage stack falls apart in practice.

Medicare Part D: the coverage gap

Medicare Part D excludes "agents when used for weight loss" under the statute at Social Security Act Section 1860D-2(e)(2)(A). That means Wegovy prescribed for obesity is not covered by Part D. Ozempic, when prescribed for diabetes, can be covered under Part D and benefits from the 2025 $2,000 annual out-of-pocket cap on covered drugs. Medicare rules may shift if future rulemaking addresses obesity as a separate covered condition, but as of early 2026 the exclusion still applies.

The indication on the prescription drives most of the coverage outcome: diabetes is broadly covered; obesity is not.

Prior authorization: why approvals take time

Most plans require prior authorization for GLP-1 medications. Common documentation requirements include a BMI threshold, one or more weight-related comorbidities, a record of prior weight-loss attempts, and a current laboratory profile. Specific thresholds vary by plan, so the most efficient path is to ask your prescriber's office whether they have a PA support team that handles GLP-1 submissions. A clean first submission with full documentation often clears in two to four weeks. A thin one can bounce back twice before approval.

How to Pay Less: Savings Programs and Self-Pay Options

Once you know your insurance situation, four levers actually move semaglutide cost in a meaningful way.

1. Novo Nordisk savings cards

Both Ozempic and Wegovy have manufacturer savings cards. Eligible commercially insured patients can pay as little as $25/month. Patients on Medicare, Medicaid, TRICARE, or any other government-funded coverage are not eligible. That exclusion is a federal compliance requirement, not a Novo Nordisk policy choice. Apply through ozempic.com or wegovy.com. Annual benefit caps and eligibility windows change periodically, so read the current terms rather than relying on what a friend told you last year.

2. NovoCare direct pharmacy (Wegovy self-pay)

NovoCare is Novo Nordisk's direct-to-patient pharmacy for Wegovy. Self-pay pricing currently starts at $149 per month for the 1.5 mg and 4 mg starter strengths. The 4 mg offer is time-bound. Novo Nordisk has stated it runs through August 31, 2026, after which the 4 mg pen rises to $199 per month. Higher maintenance doses are priced higher. Self-pay cannot be combined with insurance. Verify the current dose-by-dose price at novocare.com/pharmacy/wegovy.html, since this tier has changed twice in the last twelve months.

3. Why there is no LillyDirect equivalent for semaglutide

This is the biggest structural gap between semaglutide and tirzepatide pricing. Eli Lilly sells single-dose Zepbound vials direct-to-patient through LillyDirect at $299–$499/month. Novo Nordisk does not offer a comparable vial program for semaglutide. Wegovy is dispensed only as pre-filled autoinjector pens, and there is no Novo-direct vial format available to US cash-pay patients. The practical consequence: for someone paying cash without insurance, brand-name semaglutide has a higher floor than brand-name tirzepatide. The closest Novo equivalent is NovoCare at $149/month for starter doses, which sits below LillyDirect but is limited to the lower end of the dose range and to a limited-time offer. For the full tirzepatide breakdown, see the tirzepatide cost guide.

4. GoodRx and other discount cards

GoodRx, SingleCare, and similar services aggregate retail pharmacy discounts. Quoted prices fluctuate by ZIP code, by pharmacy chain, and over time, so a number you find today may not apply at the counter next month. They are worth checking, particularly if you do not qualify for the manufacturer savings card and want to compare a chain pharmacy to the NovoCare direct pricing. Pull a live quote at goodrx.com for your exact prescription and ZIP.

The Compounding Option: What Changed in 2025

Before 2025, compounded semaglutide ran roughly $99–$500 per month through 503A and 503B pharmacies. That market existed because the FDA had declared semaglutide on shortage in 2022, which created a legal carve-out for compounded copies. The FDA removed semaglutide from the shortage list in February 2025, and the carve-out closed soon after. Enforcement deadlines were April 22, 2025 for 503A state-licensed pharmacies and May 22, 2025 for 503B outsourcing facilities. After those dates, copy-compounding of semaglutide for standard injectable use is no longer permissible. Narrow patient-specific 503A formulations may continue where there is documented clinical need that the commercial product cannot meet, like different concentration, allergy accommodation, or combination formulation. That is a different legal pathway and a different cost structure from the bulk compounding market.

For the full regulatory sequence, read the compounded semaglutide ban timeline. For sourcing guidance on what does and does not still exist, the compounded semaglutide guide covers 503A and 503B compliance. Both articles deliberately do not duplicate the cost stack on this page.

Semaglutide Cost vs Tirzepatide: Which Costs Less?

At brand-name list price, semaglutide and tirzepatide are in the same neighborhood. The real divergence happens at the self-pay floor, because Eli Lilly sells vials and Novo Nordisk does not.

With strong commercial insurance and a savings card, either drug can land at $25/month, which equalizes the two for most insured patients. For cash-pay patients without coverage, the math is different. Zepbound vials via LillyDirect open the door at $299/month; semaglutide's closest equivalent, NovoCare's $149 starter, only covers the lower doses and is time-limited. For maintenance dosing, tirzepatide-via-vials is currently the cheaper cash-pay path. For an efficacy comparison rather than a cost comparison, see tirzepatide vs semaglutide; for brand-versus-brand on the obesity side, the Ozempic vs Wegovy comparison covers which prescription you actually want.

Is the Semaglutide Cost Worth It? A Pharmacokinetics View

The cost-benefit question on a GLP-1 is not "what do I pay this month versus what do I weigh this month." Semaglutide's half-life is about 7 days, which means a steady-state blood level only builds out after roughly four to five weeks at each dose, and the full clinical benefit accrues across many months. The STEP 1 trial reported a 14.9% average body weight loss at 68 weeks on the 2.4 mg Wegovy dose, and the SELECT trial in 2023 added cardiovascular benefit on top, the first weight-loss drug to demonstrate it. Those outcomes follow a pharmacokinetic curve, not a monthly invoice.

For patients weighing whether a $400 month or a $1,400 month is "worth it," the more useful lens is the cumulative concentration-over-time you are buying. To pin down that monthly number from your own vial price, the semaglutide cost calculator breaks it down per month, week, and milligram. The semaglutide calculator models that curve at any titration plan, and is especially useful if you are considering a slower titration, a pause, or a step-down to manage costs without unraveling the steady-state benefit. The semaglutide dosing guide covers the clinical titration schedule, and the side effects page covers what you are actually paying to tolerate.